FREMONT, Calif. — Neuralink said Friday that the U.S. Food and Drug Administration has cleared it to expand its flagship brain-computer interface study to as many as 25 participants, a significant scale-up that widens eligibility and speeds the company toward a commercial product.
The expanded authorization builds on a year of steady clinical progress and arrives shortly after Neuralink opened a speech-decoding trial aimed at restoring voice to people who have lost the ability to speak.
A Bigger, Broader Study
Until now, Neuralink's human work has proceeded a handful of patients at a time, with each implant followed closely for safety and performance. The FDA's decision lets the company enroll a much larger cohort and, crucially, broadens the eligibility criteria to include people with a wider range of motor and speech impairments.
A larger study matters for two reasons. It generates the statistical weight regulators need to eventually approve a device for general use, and it exposes the system to more varied anatomy and needs, which is how the engineering gets more robust. Neuralink said enrollment would ramp over the coming months at surgical centers in the United States, with additional international sites under review.
Faster Surgery, More Data
The expansion is possible in part because of hardware and workflow gains. Neuralink's implant surgery, performed by its R1 robot, has grown faster and more routine, and the latest implant carries far more electrode channels than the first generation. The company recently detailed a next-generation implant that doubles the number of channels, sharpening the resolution of the neural signals it can read.
More channels and more participants feed a virtuous cycle: richer data trains better decoding algorithms, which in turn let patients control cursors, keyboards, robotic limbs, and now synthesized speech with greater speed and accuracy. Early participants have already set records for the fidelity of thought-to-text and thought-to-cursor control.
Toward Everyday Use
Neuralink's stated goal is to give people with paralysis and neurological conditions a reliable way to interact with the digital world, and ultimately to help restore lost function. Each regulatory step shortens the distance between a promising research program and an approved medical device that insurers will cover. Details on the trial and how to apply are posted at neuralink.com.
With a larger trial now green-lit, the company can gather the evidence base a commercial launch will require. For patients watching from the sidelines, Friday's clearance means the door to enrollment is opening wider than ever.
